New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For IRWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
07:38 EDTIRWDIronwood announces data from Phase I IW-1973 study
Ironwood Pharmaceuticals announced top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy. Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and priority indications for the Phase II program, which will focus on areas with the highest unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016. The randomized, double-blind, placebo-controlled, single ascending dose Phase I study enrolled 46 healthy volunteers. Participants were randomized 3:1 to receive a single dose of IW-1973 or placebo administered via an oral capsule. Top-line clinical data were consistent with preclinical findings and included cardiovascular pharmacodynamic effects, dose-proportional pharmacokinetics, biomarker-based confirmation of target engagement, and evidence of extensive distribution to tissues. No serious adverse events were reported. Reported adverse events were consistent with the mechanism of action. Data from clinical and preclinical studies of IW-1973 are expected to be presented at a future medical conference.
July 15, 2015
08:21 EDTIRWDSynergy upside largely dependent on buyout, says Citi
Citi doubled its price target for Synergy Pharmaceuticals (SGYP) to $12 from $6 but cautions that upside from current levels is likely dependent on a potential takeout. The firm sees raised expectations into the new the data readout for plecanatide. The drug's effectiveness in chronic idiopathic constipation looks fairly similar to Ironwood's (IRWD) Linzess, Citi tells investors in a research note. It keeps a Buy rating on Synergy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use